BAY43-9006 - Phase II in Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer
Interventions: DRUG: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer